Leone-Bay A, Paton D R, Variano B, Leipold H, Rivera T, Miura-Fraboni J, Baughman R A, Santiago N
Emisphere Technologies, Inc., Hawthorne, New York 10532, USA.
J Control Release. 1998 Jan 2;50(1-3):41-9. doi: 10.1016/s0168-3659(97)00101-6.
Ten N-acylated, non-alpha-amino acids have been prepared as oral delivery agents and used to demonstrate the oral delivery of heparin in vivo in rats and primates. Following the oral administration of solutions containing a combination of heparin and a delivery agent to rats or primates, significant plasma heparin concentrations were evidenced by APTT and anti-Factor Xa assays. The estimated pharmacodynamic equivalence for an oral dosing solution containing heparin and a delivery agent is 39% in primates. In vitro experiments based on heparin affinity chromatography or heparin/methylene blue complexation were also performed to begin investigation of the mechanism by which these compounds facilitate heparin oral delivery. Results of in vitro studies suggest that absorption of the drug across the gastrointestinal membrane is the result of a non-covalent interaction between heparin and the delivery agent.
已制备出10种N-酰化非α-氨基酸作为口服给药载体,并用于在大鼠和灵长类动物体内证明肝素的口服给药效果。在给大鼠或灵长类动物口服含有肝素和给药载体组合的溶液后,通过活化部分凝血活酶时间(APTT)和抗Xa因子测定证明血浆肝素浓度显著升高。含有肝素和给药载体的口服给药溶液在灵长类动物中的估计药效学等效性为39%。还进行了基于肝素亲和色谱或肝素/亚甲蓝络合的体外实验,以开始研究这些化合物促进肝素口服给药的机制。体外研究结果表明,药物跨胃肠膜的吸收是肝素与给药载体之间非共价相互作用的结果。